33 results about "Nephrotoxicity" patented technology

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The invention discloses a human normal kidney immortalized cell line NRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human normal kidney immortalized cell line is named as NRC-X1, and the preservation number is CCTCC (China Center For Type Culture Collection) NO: C2025168. The invention also discloses the application of the human normal kidney immortalized cell line NRC-X1 in a virus infection mechanism. The invention also discloses application of the human normal kidney immortalized cell line NRC-X1 in research of drug renal toxicity evaluation. The invention also discloses the application of the human normal kidney immortalized cell line NRC-X1 in bioartificial kidney and cell therapy. The invention also discloses application of the human normal kidney immortalized cell line NRC-X1 in research of kidney physiological and pathological mechanisms.

The application provides a method for analyzing the synergistic mechanism of hepatotoxicity and nephrotoxicity of non-steroidal anti-inflammatory drugs. The method comprises the following steps: preliminary toxicity prediction of NSAIDs and collection of toxicity target points, collection of liver and kidney disease target points, then cross and screening of the target points to obtain core target points and common core target points of NSAIDs induced liver and kidney diseases, and then constructing a protein interaction network of the common core target points; enrichment analysis of the common core target points to obtain the common action pathway of NSAIDs induced liver and kidney diseases; finally, further screening of the common core target points to obtain the key target points of NSAIDs induced liver and kidney diseases, and verification by using molecular docking technology. Compared with the traditional method, the advantages of the method are: first, the method does not depend on large-scale patient clinical data and a large number of animal or cell experiments, avoiding the ethical controversy in animal experiments and human experiments; second, the method can identify the potential cross-pathway and synergistic toxicity mechanism when a compound triggers multiple diseases, which is helpful for more comprehensive evaluation of the toxicity risk of NSAIDs.

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

This invention belongs to the field of medical and pharmaceutical technology, and specifically relates to an antibacterial composition and its application. It comprises osimertinib mesylate and polymyxin. This invention is the first to demonstrate the novel pharmaceutical use of osimertinib mesylate as a synergistic antibacterial adjuvant for polymyxin. Experimental results show that osimertinib mesylate can significantly enhance the antibacterial activity of polymyxin against multidrug-resistant Gram-negative bacteria, effectively reduce the minimum inhibitory concentration of polymyxin, thereby reducing the clinical dosage of polymyxin and lowering the risk of its inherent nephrotoxicity and neurotoxicity. Furthermore, this invention reveals that the combined use of osimertinib mesylate and polymyxin can delay or reverse bacterial resistance to polymyxin, improve the survival rate of infected animal models, and broaden the antibacterial spectrum.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

The invention discloses application of a metabolic marker in preparation of a product for monitoring CsA renal toxicity and the product, and the metabolic marker can be used for monitoring CsA renal toxicity and is high in sensitivity, rapid, convenient and accurate and reliable in result. The metabolic marker is one or more of the following substances: phospholipid 18: 1 / 20: 0, phospholipid 20: 1 / 14: 1, lysophospholipid 18: 3, sphingolipid d18: 0 / 16: 1OH, sphingolipid d18: 0 / 24: 1OH and monoacylglycerol 20: 4 / 0: 0 / 0: 0.

The application discloses a compound soluble powder of spectinomycin hydrochloride and lincomycin hydrochloride and a preparation method thereof. Compared with the prior art, the compound soluble powder of spectinomycin hydrochloride and lincomycin hydrochloride prepared by the application has high affinity to drugs, is safe to use, significantly improves the drug dissolution speed and stability of the drug after dissolution in water and oil environments, overcomes the problems of insufficient drug dissolution and irritation of the drug to a drug administration site, reduces the hemolytic side effect of the drug for animals and the nephrotoxicity, and can also reduce the drug resistance of the drug for animals by inhibiting the function of P-sugar protein. The compound soluble powder of spectinomycin hydrochloride and lincomycin hydrochloride can expand the antibacterial spectrum and simultaneously prevent and treat various diseases by the synergistic effect of spectinomycin and lincomycin.

This invention belongs to the field of biomaterials technology, specifically relating to an integrated kidney organ-on-a-chip system and its application in online monitoring of pesticide nephrotoxicity. The integrated kidney organ-on-a-chip system includes a sample introduction device, a renal tubular microfluidic chip, a Raman detection platform, and a Raman spectrometer. The labeled antibody probe in the Raman detection platform includes a SERS substrate, and recognition antibodies and signal molecules bound to the SERS substrate. The SERS substrate is a gallium-doped zinc oxide superlattice nanocube material. This invention uses a gallium-doped zinc oxide superlattice nanocube material as the SERS substrate, integrating semiconductor surface-enhanced Raman detection technology into a kidney organ-on-a-chip, providing an online monitoring system for pesticide nephrotoxicity with advantages such as fast analysis speed, high molecular selectivity, and high detection sensitivity.

The invention relates to a ciprofloxacin dry powder inhalation particle, the dry powder inhalation particle comprises 60-95% by weight of ciprofloxacin hydrochloride and a pharmaceutically acceptable carrier, the mass median aerodynamic diameter (MMAD) of the dry powder inhalation particle is 1-5 [mu] m, and the geometric particle size distribution is that D10 is less than or equal to 2.0 [mu] m, D50 is less than or equal to 4.5 [mu] m, and D90 is less than or equal to 8.0 [mu] m. The dry powder inhalation particle can target high-concentration deposition of a lung infection part, the bioavailability is remarkably improved, and risks of renal toxicity, ototoxicity, drug resistance and the like are reduced.

The application belongs to the technical field of traditional Chinese medicines, and relates to a uremia clearing tablet and a preparation method thereof. The uremia clearing tablet comprises the following raw materials in parts by mass: 40 parts of rhubarb, 36 parts of licorice, 160 parts of astragalus, 120 parts of mulberry bark, 80 parts of sophora, 120 parts of codonopsis, 200 parts of atractylodes, 200 parts of poria, 120 parts of white peony root, 1000 parts of chrysanthemum, 200 parts of prepared rehmannia, 120 parts of chuanxiong, 200 parts of salvia, 80 parts of pinellia, 200 parts of plantain, 60 parts of bupleurum, 400-600 parts of pregelatinized starch, 100-200 parts of hydroxypropyl-beta-cyclodextrin, 80-150 parts of co-processed material, 70-100 parts of low-substituted hydroxypropyl cellulose, 10-15 parts of anhydrous calcium hydrogen phosphate, 5-8 parts of fumaric acid and 22-32 parts of lubricant. The uremia clearing tablet provided by the application has good formability, short disintegration time and good stability without coating.

The application belongs to the technical field of drug screening, analytical chemistry and pharmacology, and specifically discloses a method for screening traditional Chinese medicine active ingredients based on anti-chemotherapy drug nephrotoxicity and evaluating drug interactions. By constructing an OCT2 high-expression stable cell strain, using styrene-maleic anhydride copolymer to form OCT2 nanoliposomes, and covalently fixing the nanoliposomes on ethylene sulfone-based silica gel, an OCT2 cell membrane chromatographic column with high stability and high activity is prepared. Based on the OCT2 cell membrane chromatographic column, a two-dimensional biochromatographic method for specifically screening OCT2 binding components from traditional Chinese medicine extracts is established. With OCT2 as a specific target, the application combines high-bionic cell membrane chromatography technology, two-dimensional chromatography-mass spectrometry technology, in-vitro binding kinetics analysis, competitive drug interaction evaluation, computer simulation and in-vivo pharmacodynamic verification, and forms a complete research system from discovery to drug interaction evaluation and then to in-vivo confirmation.

This invention provides an application of *Lactobacillus plantarum* peptidoglycan in the preparation of uric acid-lowering products, relating to the biomedical field. This *Lactobacillus plantarum* peptidoglycan is derived from *Lactobacillus plantarum* (accession number CGMCC No. 25306). Lactobacillus plantarum Extracted from YC, its chemical structure is A1γ. This plant lactobacillus peptidoglycan can regulate uric acid homeostasis through multiple synergistic mechanisms: inhibiting hepatic XOD activity to reduce uric acid production; bidirectionally regulating renal and intestinal uric acid transport proteins (upregulating ABCG2 / OAT1, downregulating URAT1 / GLUT9) to promote excretion; and exerting systemic anti-inflammatory and hepatoprotective effects. This plant lactobacillus peptidoglycan has a significant uric acid-lowering effect without hepatotoxicity or nephrotoxicity, and its safety is superior to allopurinol. This invention provides a novel core material basis and solution for developing multi-pathway, highly safe uric acid-lowering products.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells, and a saponin component that enables the effective release of said medicament inside of the kidney cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney cells and, therefore, it opens not only new treatment options for kidney diseases, but also for diseases of other organs which affect the kidneys and / or which are affected by inefficient or impaired kidney function.

The invention relates to a B cell inhibitor and application thereof in preparation of drugs for treating xerophthalmia. The present invention relates to a B cell activity inhibitor selected from the group consisting of formononetin; formononin; astragaloside IV; total flavonoids of an astragalus extract; the components are astragaloside IV and formononetin; astragaloside IV and formononin; the composition is prepared from astragaloside I, astragaloside IV, formononin and formononetin. Compared with the side effect of cyclosporine in the prior art (which is within the renal toxicity of 1 / 3 of a patient who takes the medicine), the astragalus extract general flavone has the effect of inhibiting the activity of B cells so as to inhibit humoral immunity. On the basis of the research on the disease mechanism of pSS, the specific astragalus membranaceus extract general flavone which can be used as a medicine for administration and a medicine for instillation is developed.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The application belongs to the field of microorganism animal cell lines, and relates to a human normal kidney immortalized cell line NRC-X1 and application thereof. The human normal kidney immortalized cell line is named NRC-X1, and the preservation number is CCTCC NO: C2025168. The application of the human normal kidney immortalized cell line NRC-X1 in a virus infection mechanism. The application of the human normal kidney immortalized cell line NRC-X1 in research on drug nephrotoxicity evaluation. The application of the human normal kidney immortalized cell line NRC-X1 in a biological artificial kidney and cell therapy. The application of the human normal kidney immortalized cell line NRC-X1 in research on kidney physiological and pathological mechanisms.

The present disclosure provides, as an improved in vitro evaluation system for evaluating nephrotoxicity of a substance such as a compound, a method for evaluating nephrotoxicity of a test substance comprising a step of contacting a test substance with a kidney organoid, wherein the higher cytotoxicity of test substance as compared with a control substance indicates the test substance is likely to have nephrotoxicity.

The invention relates to a snake venom capsule for treating alopecia, which aims at the problems that the alopecia is complicated in pathogenesis and the existing treatment method is limited, takes agkistrodon acutus venom, trimeresurus venom and cobra venom as main active ingredients, and is matched with 17 traditional Chinese medicines such as polygonum multiflorum, prepared rehmannia root, semen cuscutae and the like. The snake venom is treated by adopting an ultralow-temperature freeze-drying technology, the retention rate of active enzyme is ensured to be greater than or equal to 90%, and the capsule is prepared through the steps of raw material treatment, scientific compatibility and mixing, a granulation process, capsule filling and the like. The capsule accurately activates hair follicle stem cells in a targeted manner through snake venom active enzyme, promotes hair follicle microangiogenesis, forms an activation-flow increasing-anti-inflammatory-hair consolidation closed-loop treatment system with a traditional Chinese medicine formula, can effectively treat alopecia, preclinical research shows that the hair density of a patient is averagely increased by 45%-65% after the patient continuously takes the capsule for 3 months, and the capsule does not have obvious liver and kidney toxic reaction and has a good treatment effect on alopecia. A safe, efficient and economical treatment choice is provided for alopecia patients.

The invention discloses an application of an MCP-1 inhibitor in preparation of a medicine for preventing and treating aging-related pathological myocardial hypertrophy, the experiment reveals that MCP-1 is an aging-related pathological myocardial hypertrophy core regulatory factor for the first time, and the MCP-1 is used for up-regulating the protein expression of GATA4, IL-17A, NF-kB-p65 signals, alpha-SMA and Collagen I by activating an IL-17A / MCP-1 / CCR2 / IL-17A signal loop, so that the effect of preventing and treating the aging-related pathological myocardial hypertrophy is achieved. Further, myocardial cell senescence and senescence-related secretory phenotypes, hypertrophy and fibrosis are induced. Experiments prove that the MCP-1 inhibitor can be used for preventing and treating the SA-PCH, can improve the SA-PCH induced by Ang II and / or IL-17A, is free of liver and kidney toxicity and can obviously improve liver and kidney function decline induced by Ang II, and a new way is provided for clinical treatment of the SA-PCH.

This invention relates to the field of microbial technology, and in particular to a short-fermenting Lactobacillus strain capable of significantly preventing the progression of kidney disease and stabilizing renal function, and its uses. The strain of this invention has shown good efficacy in various kidney disease models, especially in a cisplatin-induced CKD model, significantly alleviating weight loss induced by platinum-based drugs in mice; it also provides excellent protection against platinum-based drug-induced intestinal inflammation and intestinal wall integrity; in the long term, it significantly alleviates platinum-based drug nephrotoxicity; it has a good stabilizing effect on renal function and can effectively prevent the progression of CKD. Therefore, the described strain can be used to prepare pharmaceutical compositions for stabilizing and improving renal function in acute and chronic kidney diseases, and can also be used to prepare drugs that reduce drug side effects, showing very broad application prospects.

The invention provides a method for analyzing a combined action mechanism of hepatotoxicity and renal toxicity of a non-steroidal anti-inflammatory drug. The method comprises the following steps: preliminary toxicity prediction of NSAIDs, toxic action target collection, liver and kidney disease target collection, target crossing and screening to obtain a core target and a common core target of the NSAIDs induced liver and kidney diseases, and further constructing a protein interaction network of the common core target. Carrying out enrichment analysis on the common core target spot to obtain a common action way of inducing the liver and kidney diseases by the NSAIDs; and finally, further screening the common core target spot to obtain a key target spot of the NSAIDs-induced liver and kidney disease, and verifying by using a molecular docking technology. Compared with a traditional method, the method has the advantages that firstly, the method does not depend on large-scale patient clinical data and a large number of animal or cell experiments, and ethical disputes in animal experiments and human body experiments are avoided; and secondly, the method can identify potential cross pathways and synergistic toxicity mechanisms when the compound causes various diseases, and is beneficial to more comprehensively evaluating the toxicity risk of the NSAIDs.

This invention belongs to the field of pet food processing and relates to a premix for improving the urinary tract health of pets. The premix contains the following components in parts by weight: 25-35 parts of Dioscorea opposita, 25-35 parts of Poria cocos, 15-25 parts of Taraxacum mongolicum, 15-25 parts of Centella asiatica, 15-25 parts of Plantago asiatica, 5-15 parts of Polygonatum sibiricum, 5-15 parts of Cornus officinalis, and 5-15 parts of Lycium barbarum. Adding this premix to the cat's diet reduces serum creatinine, blood urea nitrogen, and serum oxalate concentrations, affecting oxalate absorption and excretion, and preventing the formation of calcium oxalate stones. This premix can alleviate the nephrotoxicity of sodium oxalate in cats, improve renal physiological indicators, reduce the formation of calcium oxalate stones, and provide a basic guarantee for the treatment of chronic urinary system diseases. This premix can improve the urinary tract health of cats.

Nicotinamide mononucleotide derivatives of Formula (I)for use in the treatment and / or prevention of an antineoplastic-induced toxicity. Also, pharmaceutical compositions that include compounds of Formula (I) for use in the treatment and / or prevention of an antineoplastic-induced toxicity selected from cardiotoxicity, nephrotoxicity, haematotoxicity, hepatotoxicity, lymphoid toxicity, gastrointestinal toxicity, dermal toxicity, reproductive toxicity, bone toxicity, genetic toxicity and bladder toxicity.

This invention discloses a metal-coordinated iohexol nanoparticle, its preparation method, and its applications. The metal-coordinated iohexol nanoparticles of this invention are prepared by reacting a metal salt with iohexol in an organic medium; the particle size range of the metal-coordinated iohexol nanoparticles is 50-100 nm. This invention synthesizes metal-coordinated iohexol nanoparticles via a one-pot method, which is simple and does not require multiple reaction steps. The metal-coordinated iohexol nanoparticles prepared by this invention mainly accumulate in the liver, with only a small amount accumulating in the kidneys. They can significantly reduce the nephrotoxicity of chronic renal failure model mice after CT imaging, and exhibit good biocompatibility and almost no cytotoxicity in vitro.

This invention provides the application of an S100A6 inhibitor in the preparation of a drug for treating calcium oxalate stones. This invention is the first to discover that S100A6 plays a crucial role in the formation of calcium oxalate stones. It promotes STAT3 phosphorylation, upregulates the expression of NADPH oxidase subunits p67phox and p40phox, promotes reactive oxygen species (ROS) generation, and induces autophagy and apoptosis in renal epithelial cells, thereby promoting calcium oxalate stone formation. Furthermore, the S100A6 small molecule inhibitor AP-048 provided by this invention specifically binds to S100A6. In vitro and in vivo experiments have confirmed that AP-048 can significantly inhibit calcium oxalate crystal cell adhesion, reduce ROS levels, decrease renal crystal deposition, alleviate renal tubular damage and inflammatory factor expression, and has no significant hepatotoxicity or nephrotoxicity. This invention provides a new target and therapeutic strategy for calcium oxalate stones, with promising clinical application prospects.